

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ARGENICA THERAPEUTICS LIMITED
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	GEOFF POCOCK
Date of last notice	9 JUNE 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	CONTROLLER OF TRUSTEE AND BENEFICIARY
Date of change	1. 10 JUNE 2022 2. 14 JUNE 2022
No. of securities held prior to change	OOFY PROSSER PTY LTD <DRONES FAMILY A/C> 4,377,000 – FULLY PAID ORDINARY SHARES 500,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.30, EXPIRY DATE 30 SEP 2024
Class	ORDINARY SHARES
Number acquired	1. 32,690 2. 27,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	NIL
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. \$13,532.40 2. \$11,070.00
No. of securities held after change	OOFY PROSSER PTY LTD <DRONES FAMILY A/C> 4,436,690 – FULLY PAID ORDINARY SHARES 500,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.30, EXPIRY DATE 30 SEP 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	ON MARKET PURCHASE

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ARGENICA THERAPEUTICS LIMITED
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	LIZ DALLIMORE
Date of last notice	9 JUNE 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	TRUSTEE AND BENEFICIARY
Date of change	1. 10 JUNE 2022 2. 14 JUNE 2022
No. of securities held prior to change	LEWIS MACDONALD DAWSON & ELIZABETH JANE DAWSON <DAWSON FAMILY A/C> 2,500,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.30, EXPIRY DATE 30 SEP 2024
Class	ORDINARY SHARES
Number acquired	1. 39,084 2. 10,916
Number disposed	NIL

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	1. \$15,633.60 2. \$4,366.40
No. of securities held after change	LEWIS MACDONALD DAWSON & ELIZABETH JANE DAWSON <DAWSON FAMILY A/C> 50,000 – FULLY PAID ORDINARY SHARES 2,500,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.30, EXPIRY DATE 30 SEP 2024
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	ON MARKET PURCHASE

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.